JPRN-jRCT2080221435未知3 期
A Randomised, Double-blind, Double-dummy, Parallel Group, International (Asian), Multicenter, Phase 3 Study to Assess Safety and Efficacy of AZD6140 on Top of Low Dose Acetyl Salicylic Acid (ASA) Versus Clopidogrel on Top of Low Dose ASA in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes(ACS) for Whom PCI is Planned
适应症
试验速览
- 阶段
- 3 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Provision of signed informed consent
- •- Index event of non-ST or ST segment elevation ACS
排除标准
- •- Index event is an acute complication of percutaneous coronary intervention
- •- Patient has undergone Percutaneous Coronary Intervention (PCI) after the index event before the first dose of study treatment
- •- Oral anticoagulation therapy that cannot be stopped
- •- The conditions associated with increased risk of bradycardiac events
研究者
相似试验
尚未招募
3 期
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple SclerosisRelapsing Multiple SclerosisLBCTR2023015151ovartis Pharma AG16
招募中
1 期
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treatment with remibrutinibMultiple SclerosisCTIS2023-509345-12-00ovartis Pharma AG800
进行中（未招募）
不适用
A randomized, double-blind, double-dummy, parallel group study of the safety and efficacy of MRA monotherapy, versus methotrexate (MTX) monotherapy, in patients with active rheumatoid arthritis.Rheumatoid ArthritisEUCTR2005-001138-33-LTF. Hoffmann La-Roche AG650
进行中（未招募）
1 期
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treatment with remibrutinibMultiple SclerosisEUCTR2020-005899-36-ESovartis Farmacéutica S.A.800
进行中（未招募）
1 期
Efficacy and safety of a progestin and an aromatase inhibitor combined in a intravaginal ring in symptomatic endometriosis.EndometriosisEUCTR2013-005090-53-CZBayer AG318